18.56

5.31% -1.04

Tyra Biosciences Inc (TYRA)

Overview News Price History Option Chain Financials Discussions Forecast

Tyra Biosciences Inc stock is traded at $18.56, with a volume of 469.54K. It is down -5.31% in the last 24 hours and down -15.75% over the past month. Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Previous Close:

$19.60

Open:

$19.39

24h Volume:

469.54K

Relative Volume:

0.66

Market Cap:

$1.28B

Revenue:

Net Income/Loss:

$-131.11M

P/E Ratio:

-8.5353

EPS:

-2.1745

Net Cash Flow:

$-102.47M

1W Performance:

-8.30%

1M Performance:

-15.75%

6M Performance:

-47.89%

1Y Performance:

+29.25%

1-Day Range:

$18.54

$19.60

1-Week Range:

$18.54

$20.79

52-Week Range:

$13.35

$40.65

Tyra Biosciences Inc Stock (TYRA) Company Profile

Name

Tyra Biosciences Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(619) 728-4760

Address

2656 STATE STREET, CARLSBAD

Employee

Twitter

Next Earnings Date

2026-11-04

Latest SEC Filings

TYRA's Discussions on Twitter

Compare TYRA vs VRTX, MRNA, REGN, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TYRA Tyra Biosciences Inc	18.56	1.28B	0	-131.11M	-102.47M	-2.1745
VRTX Vertex Pharmaceuticals Inc	485.22	122.98B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	216.25	86.33B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	753.12	77.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	802.64	50.47B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.44	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-19-26	Initiated	Wolfe Research	Peer Perform
Apr-15-26	Initiated	Guggenheim	Buy
Apr-06-26	Initiated	Canaccord Genuity	Buy
Feb-24-26	Initiated	Cantor Fitzgerald	Overweight
Feb-10-26	Initiated	William Blair	Outperform
Jan-28-26	Initiated	Barclays	Overweight
Sep-03-25	Initiated	Raymond James	Strong Buy
May-21-25	Resumed	Piper Sandler	Overweight
Jan-07-25	Initiated	UBS	Buy
Oct-18-24	Upgrade	BofA Securities	Neutral → Buy
Aug-15-24	Initiated	Piper Sandler	Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Jun-30-23	Initiated	Wedbush	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Jun-23-22	Initiated	H.C. Wainwright	Buy
Mar-08-22	Upgrade	Jefferies	Hold → Buy
Nov-08-21	Downgrade	Jefferies	Buy → Hold
Oct-11-21	Initiated	BofA Securities	Buy
Oct-11-21	Initiated	Cowen	Outperform
Oct-11-21	Initiated	Jefferies	Buy

View All

Tyra Biosciences Inc Stock (TYRA) Latest News

Oct 06, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc.TYRA - GlobeNewswire Inc.

Oct 06, 2026

Oct 02, 2026